Rigel Pharmaceuticals Stock Forecast, Price & News

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

Is Rigel Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rigel Pharmaceuticals stock.
View analyst ratings for Rigel Pharmaceuticals or view top-rated stocks.

How has Rigel Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RIGL shares have increased by 53.0% and is now trading at $2.77.
View which stocks have been most impacted by COVID-19.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Rigel Pharmaceuticals.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.02. The biotechnology company earned $21.54 million during the quarter, compared to the consensus estimate of $24.16 million. Rigel Pharmaceuticals had a negative net margin of 9.85% and a negative trailing twelve-month return on equity of 25.22%. During the same quarter last year, the company earned ($0.08) EPS.
View Rigel Pharmaceuticals' earnings history.

What price target have analysts set for RIGL?

2 Wall Street analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $9.50 in the next year. This suggests a possible upside of 243.0% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:

• Raul R. Rodriguez, President, Chief Executive Officer & Director
• Dean L. Schorno, Chief Financial Officer & Executive Vice President
• Wolfgang Dummer, Chief Medical Officer & Executive Vice President
• David Santos, Chief Commercial Officer & Executive VP
• Joseph Lasaga, Senior Vice President-Corporate Development

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals CEO Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among Rigel Pharmaceuticals' employees.

Who are some of Rigel Pharmaceuticals' key competitors?

Some companies that are related to Rigel Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of RIGL's competitors.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.78%), Invesco Ltd. (3.03%), Rock Springs Capital Management LP (2.80%), Lord Abbett & CO. LLC (2.56%), Millennium Management LLC (2.37%) and Geode Capital Management LLC (1.82%).
View institutional ownership trends for Rigel Pharmaceuticals.

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Millennium Management LLC, Citigroup Inc., Morgan Stanley, Schonfeld Strategic Advisors LLC, Oppenheimer & Co. Inc., Panagora Asset Management Inc., and Two Sigma Investments LP.
View insider buying and selling activity for Rigel Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including HealthInvest Partners AB, Laurion Capital Management LP, Dimensional Fund Advisors LP, Great Point Partners LLC, Goldman Sachs Group Inc., Hudson Bay Capital Management LP, Brandywine Global Investment Management LLC, and Summit Global Investments.
View insider buying and selling activity for Rigel Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $2.77.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals has a market capitalization of $473.69 million and generates $108.62 million in revenue each year. The biotechnology company earns $-29.74 million in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals employs 169 workers across the globe.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

Where are Rigel Pharmaceuticals' headquarters?

Rigel Pharmaceuticals is headquartered at 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 624-1100, via email at [email protected], or via fax at 650-624-1101.